IRD
Opus Genetics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IRD
Opus Genetics, Inc.
A clinical stage ophthalmic biopharmaceutical company developing treatments for hereditary retinal diseases (IRD) and other retinal and refractive disorders
8 Davis Drive, Suite 220, Durham, NC 27709
--
Opus Genetics, Inc., is a clinical-stage ophthalmic biopharmaceutical company dedicated to the development and commercialization of therapies for the treatment of a variety of eye diseases. Ocuphire's product line currently includes two small molecule product candidates for ocular indications. The Company's lead product candidate, Nyxol Eye Drops, is a once-daily preservative-free phentolamine mesylate eye drop formulation, a non-selective α-1 and α-2 adrenergic antagonist designed to reduce pupil size, and is currently under development for several indications, including dim light or night vision disorder, pharmacological mydriasis and presbyopia. Ocuphire's second product candidate, APX 3330, is a twice-daily oral tablet designed to inhibit angiogenesis and inflammatory pathways associated with retinal and choroidal vascular diseases such as diabetic retinopathy and diabetic macular edema.
Company Financials
EPS
IRD has released its 2025 Q3 earnings. EPS was reported at -0.25, versus the expected -0.13, missing expectations. The chart below visualizes how IRD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IRD has released its 2025 Q3 earnings report, with revenue of 3.08M, reflecting a YoY change of -20.38%, and net profit of -17.45M, showing a YoY change of -131.92%. The Sankey diagram below clearly presents IRD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
